Read later
  • 20 Nov 2020

AlpVision to protect Covid-19 medication for free

AlpVision has launched a Covid-19 initiative helping pharmaceutical companies to protect medicines against counterfeiting

AlpVision, a Swiss specialist in digital anti-counterfeiting technologies for product authentication and counterfeit protection, has launched the AlpVision Covid-19 Initiative helping pharmaceutical companies to protect medicines against counterfeiting.

The Covid-19 pandemic has caused not a worldwide health crisis and created unprecedented economic challenges. In response, AlpVision has decided to launch the AlpVision Covid-19 Initiative to supports pharmaceutical companies by providing them with free tools to protect relevant medicines and vaccines against counterfeiting.

The company will provide pharmaceutical companies and their suppliers with all necessary tools to deploy the Cryptoglyph digital security feature which can be implemented and deployed within just a few weeks. It is invisible to the human eye and uses a regular smartphone for product authentication. 

Securing of packaging doesn’t require any changes to the standard production process, nor requires additional consumables. In addition, the smartphone applications connect to AlpVision’s Brand Monitoring System (BMS), a centralized server platform through which pharmaceutical companies are able to monitor in real-time product authentication activities and gain important insight into counterfeiting activities.

The initiative will run for an initial period of three months. Participating companies will be able to protect their Covid-19 relevant products without additional cost for the authentication feature. AlpVision will provide this service until the pandemic is officially declared as ended by the World Health Organization. 


The Labels & Labeling global editorial team covers every corner of the world from Europe and the Americas, to India, Asia, Southeast Asia and Australasia with all the latest news from the label and package printing market.

See author’s profile »